A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection

NCT ID: NCT00210639

Last Updated: 2014-04-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2233 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-08-31

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the long-term safety of levofloxacin administered to children as therapy for acute bacterial infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective (look forward using periodic observations collected predominantly following participant enrollment), long-term, comparative, multicenter, observational study (study in which the investigators/physicians observe the participants and measure their outcomes) to monitor long-term the incidence of musculoskeletal (MS) disorders in children who have received levofloxacin or a standard therapy for acute bacterial infection. Approximately 2500 participants who were enrolled in prior Phase 3 clinical studies of the use of levofloxacin for the treatment of acute infectious disease will be observed in this study. The study consists of 3 phases: a screening phase; a surveillance phase; and a musculoskeletal disorder follow-up phase. Safety evaluations will include assessment of an overall incidence of musculoskeletal disorders that occur during the first 60 days after the first dose of anti-microbial therapy. The specific musculoskeletal disorders to be reported are: tendinopathy (inflammation or rupture of a tendon); arthritis (inflammation of a joint as shown by redness or swelling); arthralgia (pain in a joint); gait abnormality (limping or refusal to walk). Other assessments of safety will include interviews using standardized questionnaires to assess the occurrence of musculoskeletal adverse events, physical examinations, and measurement of participants height over the course of 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Musculoskeletal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Levofloxacin-treated cohort

Participants receiveing levofloxacin in previous levofloxacin studies will be observed.

No intervention

Intervention Type DRUG

This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.

Comparator-treated cohort

Participants receiveing comparator in previous levofloxacin studies will be observed.

No intervention

Intervention Type DRUG

This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have taken at least 1 dose of levofloxacin or standard non-fluoroquinolone therapy as part of a Phase 3 levofloxacin clinical study (LOFBIV-PCAP-003, LOFBO-OTMD-001, LOFBO-OTMD-002) to treat an acute bacterial infection
* Parent or legal guardian read and signed the informed consent form

Exclusion Criteria

* Participants who do not meet the criteria for enrollment in a prior Phase 3 clinical study of levofloxacin or did not take at least one dose of levofloxacin or standard non-fluoroquinolone therapy in 1 of 3 prior Phase 3 levofloxacin clinical studies (LOFBIV-PCAP-003, LOFBO-OTMD-001, or LOFBO-OTMD-002)
Minimum Eligible Age

6 Months

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johnson & Johnson Pharmaceutical Research and Development, L.L .C.Clinical Trial

Role: STUDY_DIRECTOR

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hoover, Alabama, United States

Site Status

Mobile, Alabama, United States

Site Status

Phoenix, Arizona, United States

Site Status

Tucson, Arizona, United States

Site Status

Madera, California, United States

Site Status

Oakland, California, United States

Site Status

Orange, California, United States

Site Status

Paramount, California, United States

Site Status

San Luis Obispo, California, United States

Site Status

West Covina, California, United States

Site Status

Centennial, Colorado, United States

Site Status

Denver, Colorado, United States

Site Status

Chiefland, Florida, United States

Site Status

Hollywood, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Blue Ridge, Georgia, United States

Site Status

Marietta, Georgia, United States

Site Status

‘Aiea, Hawaii, United States

Site Status

Boise, Idaho, United States

Site Status

Nampa, Idaho, United States

Site Status

Chicago, Illinois, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Bardstown, Kentucky, United States

Site Status

Louisville, Kentucky, United States

Site Status

Metairie, Louisiana, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Slidell, Louisiana, United States

Site Status

Detroit, Michigan, United States

Site Status

Royal Oak, Michigan, United States

Site Status

Stevensville, Michigan, United States

Site Status

Omaha, Nebraska, United States

Site Status

Johnson City, New York, United States

Site Status

Mineola, New York, United States

Site Status

New York, New York, United States

Site Status

Rochester, New York, United States

Site Status

Akron, Ohio, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Charleston, South Carolina, United States

Site Status

Corpus Christi, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Seguin, Texas, United States

Site Status

Burke, Virginia, United States

Site Status

Vienna, Virginia, United States

Site Status

Buenos Aires, , Argentina

Site Status

Loma Hermosa, , Argentina

Site Status

San Isidro, , Argentina

Site Status

Curitiba, , Brazil

Site Status

Porto Alegre, , Brazil

Site Status

São Paulo, , Brazil

Site Status

Santiago, , Chile

Site Status

Costa Rica, , Costa Rica

Site Status

San José, , Costa Rica

Site Status

Beersheba, , Israel

Site Status

Guadalajara, , Mexico

Site Status

Puebla City, , Mexico

Site Status

Toluca, , Mexico

Site Status

Zapopan, , Mexico

Site Status

Zona, , Panama

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Brazil Chile Costa Rica Israel Mexico Panama

References

Explore related publications, articles, or registry entries linked to this study.

Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007 Oct;26(10):879-91. doi: 10.1097/INF.0b013e3180cbd382.

Reference Type RESULT
PMID: 17901792 (View on PubMed)

Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014 Jul;134(1):e146-53. doi: 10.1542/peds.2013-3636. Epub 2014 Jun 2.

Reference Type DERIVED
PMID: 24918220 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=57&filename=CR004171_CSR.pdf

A long-term study of the incidence of musculoskeletal disorders in children who have received levofloxacin or a standard non-fluoroquinolone therapy for acute bacterial infection

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LOFBO-LTSS-001

Identifier Type: OTHER

Identifier Source: secondary_id

PRI/LOF-INT-4

Identifier Type: OTHER

Identifier Source: secondary_id

CR004171

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.